Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ramucirumab with Trastuzumab and Chemo in HER2+ Gastric/GEJ Cancer
NCT02726399Phase 2Terminated
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Mar 2016
- Primary completion
- Feb 2019
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ramucirumab in gastric cancer (GC) and gastroesophageal junction cancer, sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Progression Free Survival at 6 months. Started Mar 2016; status: terminated.
02
Drugs
ramucirumab
03
Conditions
gastric cancer (GC)gastroesophageal junction cancer
Beyond the preview
Go deeper on NCT02726399.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02726399.